New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
07:59 EDTGEVASynageva should be bought at current levels, says RW Baird
Baird said their investment thesis for Synageva remains unchanged following its successful display at the WORLD symposium last month. The firm recommends purchase at current levels as the company heads into an important value-creating period which includes potential pivotal data for a lead compound and the beginning of clinical trials for SBC-103. Shares are Outperform rated with a $107 price target.
News For GEVA From The Last 14 Days
Check below for free stories on GEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
07:07 EDTGEVASynageva appoints Robert Bazemore as COO
Synageva announced the appointment of Robert Bazemore as Chief Operating Officer. Bazemore will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations. Bazemore last served at Johnson & Johnson (JNJ) in varoius roles including Vice President, Ethicon New Growth Platforms and President of Janssen Biotech, a part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use